Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BL-B01D1 combined with serplulimab in extensive-stage small cell lung cancer
CTR20241906Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jul 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of izalontamab brengitecan, serplulimab and anlotinib in small cell lung cancer (SCLC), sponsored by Biokin Pharmaceutical. Primary endpoints: Objective response rate and Recommended phase 2 dose for the combination. Started Jul 2024; status: active.
02
Drugs
izalontamab brengitecanserplulimabanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20241906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241906.